A Randomized, Double-blind, Placebo- and Comparator-controlled Study Evaluating the Effect of Multiple Doses of QGE031 Compared to Omalizumab in Asthma Induced by Allergen Bronchial Provocation
Phase of Trial: Phase I/II
Latest Information Update: 07 Apr 2016
Price : $35 *
At a glance
- Drugs Ligelizumab (Primary) ; Omalizumab
- Indications Allergic asthma
- Focus Pharmacogenomic; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 27 Jan 2014 As per the Clinicaltrials.gov record, status changed from active, no longer recruiting to completed.
- 04 Jun 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 16 Feb 2013 New source identified and integrated (EudraCT2012-003350-84: European Clinical Trials Database).